drugset / Trial / NCT00945724

Safety and Feasibility Study of Combination of State of Art Chemoimmunotherapy, Intensive Central Nervous System Prophylaxis and Scrotal Irradiation to Treat Primary Diffuse Large B-cell Lymphoma of Testis

NCT00945724

NaSingle-groupOpen-labelTreatment

Summary

This trial is a phase II non-comparative study aimed to determine the feasibility and toxicity of the R-CHOP regimen in combination with intrathecal liposomal cytarabine and systemic intermediate-dose methotrexate followed by loco-regional radiotherapy.

Timeline

Start
2009-09-27
Primary completion
2019-06
Completion
2023-09-26

Drugs

EvaluationDrugModalityDoseRoute
Subject Cyclophosphamide Other / unclassified
Subject Cytarabine Small molecule 50 mg Intrathecal
Subject Doxorubicin Other / unclassified
Subject Methotrexate Small molecule 1.5 g Intravenous
Subject Prednisolone Other / unclassified
Subject Rituximab Monoclonal antibody 375 mg/m2
Subject Vincristine Small molecule